93 related articles for article (PubMed ID: 28153859)
1. DLBCL Responds Well to Anti-CD19 CAR Therapy.
Cancer Discov; 2017 Mar; 7(3):241-242. PubMed ID: 28153859
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
3. CAR T-cell therapy in refractory large B-cell lymphoma.
Stirrups R
Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
[No Abstract] [Full Text] [Related]
4. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
5. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor TÂ Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
6. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
[TBL] [Abstract][Full Text] [Related]
7. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Chow VA; Gopal AK; Maloney DG; Turtle CJ; Smith SD; Ujjani CS; Shadman M; Cassaday RD; Till BG; Tseng YD; Warren EH; Shustov AR; Menon MP; Bhark S; Acharya UH; Mullane E; Hannan LM; Voutsinas JM; Gooley TA; Lynch RC
Am J Hematol; 2019 Aug; 94(8):E209-E213. PubMed ID: 31056762
[No Abstract] [Full Text] [Related]
9. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Havard R; Stephens DM
Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
[TBL] [Abstract][Full Text] [Related]
10. Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.
Jain MD
Mol Ther; 2022 Jan; 30(1):14-16. PubMed ID: 34921770
[No Abstract] [Full Text] [Related]
11. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
12. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
13. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.
Abramson JS; McGree B; Noyes S; Plummer S; Wong C; Chen YB; Palmer E; Albertson T; Ferry JA; Arrillaga-Romany IC
N Engl J Med; 2017 Aug; 377(8):783-784. PubMed ID: 28834486
[No Abstract] [Full Text] [Related]
15. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
Chen R; Song XT; Chen B
Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
[TBL] [Abstract][Full Text] [Related]
16. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
Gill S; Porter DL
Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.
Quintana M; Li DH; Albertson TM; Connor JT
Contemp Clin Trials; 2016 May; 48():153-65. PubMed ID: 27109037
[TBL] [Abstract][Full Text] [Related]
18. [Application of flow cytometry in diagnosis of T-cell rich diffuse large B-cell lymphoma].
Xia CQ; Qi M; Xu XF; Li LH; Zhao HY
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):29-32. PubMed ID: 17374235
[TBL] [Abstract][Full Text] [Related]
19. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
20. Lulla PD. CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2021;139(9):1266-1267.
Blood; 2022 Dec; 140(24):2646. PubMed ID: 36520468
[No Abstract] [Full Text] [Related]
[Next] [New Search]